Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Fed Rate Cut Signals Balance Between Inflation and Jobs, Says Mary Daly 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Celltrion biopharmaceutical company headquartered in Incheon, South Korea, recently signed a deal with San Jose, California-based biotherapeutics company. They have teamed up to jointly carry out research and development of an oral antibody medicine.
Celltrion and Rani Therapeutics named their project RT-111 and they will work together to create the said drug with ustekinumab which is an autoimmune ingredient. As per Pulse News, the medicine is for oral treatment and mentioned that ustekinumab is being sold under the name of Stelara by Janssen Pharmaceuticals.
This is normally used for treating ulcerative colitis and Crohn’s disease. For this project, the companies will use it to develop an antibody medicine.
The US-based biotherapeutics firm has the technology to turn intravenous and subcutaneous injection-type proteins and antibody therapies into oral medicines. And under the agreement, Celltrion will be supplying its biosimilar CT-P43 referencing Stelara to Rani Therapeutic‘s clinical and non-clinical tests for RT-111.
The deal also states that the latter has a preferential right to develop and bring medicine to the global market. It was noted that ustekinumab has already been approved in the United States so it can be freely used as an ingredient in RT-111.
“We are delighted to be partnering with Celltrion, a leader in biosimilars and biologics manufacturing, on RT-111,” Rani Therapeutics’ chief executive officer, Talat Imran, said in a press release. “This agreement is a validation of our RaniPill oral drug delivery technology, which has already performed well in two separate Phase 1 trial of RT-101 and RT-102, respectively.”
The CEO added, “We value Celltrion as the exclusive provider of ustekinumab biosimilar for our RT-111 program and look forward to sharing the results of our study in due course, and potentially broadening our partnership with Celltrion.”
Celltrion’s head of medical science unit, Kim Sung Hyun, also commented on its new partnership deal with Rani by saying, “Celltrion strives to address unmet needs of patients and partnering with Rani offers the opportunity to replace painful injections with a pill.”
